Global IV and Oral Iron Drugs Market Size By Type (Oral Iron Drug, IVIron Drugs), By Application (Nephrology, OBGYN), By Region, And Segment Forecasts, 2023 to 2032

The Global IV and Oral Iron Drugs Market was valued at USD 4.1 billion in 2023 and is projected to reach USD 7.3 billion by 2031, expanding at a CAGR of 7.2% during the forecast period of 2023–2031. The market is experiencing robust growth due to the rising prevalence of iron deficiency anemia, chronic kidney diseases, and gastrointestinal disorders that affect iron absorption. Increased awareness of nutritional deficiencies, the expanding geriatric population, and advancements in drug formulation and delivery systems are also driving the demand for both intravenous and oral iron therapies globally.

Drivers:

1. Rising Prevalence of Iron Deficiency Anemia:

Iron deficiency is one of the most common nutritional disorders worldwide, particularly among women, children, and the elderly. The increasing burden of anemia is pushing healthcare providers to prescribe iron supplements in both oral and intravenous forms.

2. Growing Incidence of Chronic Diseases:

Chronic conditions such as chronic kidney disease (CKD), cancer, and inflammatory bowel disease often impair iron absorption or increase iron requirements. This fuels demand for parenteral iron therapies where oral administration is ineffective.

3. Technological Advancements in Formulations:

The development of next-generation iron drugs with improved bioavailability, reduced gastrointestinal side effects, and faster infusion times (e.g., ferric carboxymaltose) is accelerating adoption across developed and emerging markets.

Restraints:

1. Adverse Effects and Product Recalls:

Both oral and IV iron drugs can cause side effects, such as gastrointestinal irritation (oral) and hypersensitivity reactions (IV). These safety concerns, combined with the occasional product recalls, can hinder patient compliance and market growth.

2. Preference for Alternative Therapies:

The availability of dietary interventions and erythropoiesis-stimulating agents (ESAs) as alternatives to iron therapy may challenge market expansion, particularly in developed healthcare settings with access to diverse treatment modalities.

Opportunity:

1. Market Penetration in Emerging Economies:

Regions such as Asia-Pacific, Latin America, and Africa present significant growth potential, driven by underdiagnosed anemia, improving healthcare infrastructure, and government-led awareness campaigns.

2. Rise of Home-based Iron Therapies:

Advancements in self-administration technologies and portable infusion devices are creating opportunities for patients to manage iron deficiency from home, increasing convenience and adherence.

Market by System Type Insights:

IV Iron Drugs Segment:

The IV iron segment accounted for the largest revenue share in 2023. Its dominance is attributed to the increasing number of patients who are either intolerant to or do not respond to oral iron therapies, especially in hospital settings and for chronic conditions like CKD and cancer.

Oral Iron Drugs Segment:

Oral iron drugs remain widely used due to their lower cost and ease of administration. New formulations aimed at minimizing side effects and improving absorption are enhancing the segment’s performance, especially in outpatient and developing markets.

Market by End-use Insights:

Hospitals and Clinics:

In 2023, hospitals and clinics were the dominant end-use segment due to the controlled administration of IV iron in inpatient and dialysis settings. The presence of trained professionals ensures patient safety during IV iron infusions.

Retail Pharmacies and Homecare:

This segment is gaining momentum due to the growing demand for oral supplements and increasing availability of IV formulations designed for home infusion. The trend toward personalized and decentralized healthcare is expected to drive further growth.

Market by Regional Insights:

North America:

Held the largest share in 2023, owing to high awareness, reimbursement coverage, and a growing elderly population prone to chronic illnesses requiring iron therapy.

Asia-Pacific:

Poised to witness the fastest CAGR during the forecast period, supported by increasing anemia prevalence, healthcare reforms, and expanding pharmaceutical distribution networks in India, China, and Southeast Asia.

Europe:

Continues to show strong demand due to robust healthcare infrastructure, favorable policies, and the introduction of cost-effective biosimilars.

Competitive Scenario:

Key players in the Global IV and Oral Iron Drugs Market include:

Vifor Pharma

AMAG Pharmaceuticals (now a part of Covis Pharma)

Sanofi

Pharmacosmos

Shield Therapeutics

Daiichi Sankyo

Akebia Therapeutics

Pfizer Inc.

Hikma Pharmaceuticals

Fera Pharmaceuticals

These companies are focused on expanding their geographic reach, launching novel iron formulations, and obtaining regulatory approvals to strengthen their market position. For instance:

In 2023, Pharmacosmos launched its new IV iron formulation in the U.S. to meet growing demand among CKD patients.

In 2024, Shield Therapeutics expanded its commercial partnerships to distribute oral iron drugs in emerging Asian markets.

Scope of Work – Global IV and Oral Iron Drugs Market

Key Market Developments:

July 2023: Sanofi announced a strategic collaboration to develop an extended-release oral iron drug with enhanced bioavailability.

April 2024: Vifor Pharma expanded its manufacturing capabilities in Europe to meet rising demand for IV iron therapies.

February 2025: Shield Therapeutics received regulatory approval for its oral iron product in Japan, expanding its international footprint.

FAQs:

1) What is the current market size of the Global IV and Oral Iron Drugs Market?

The market size was valued at USD 4.1 billion in 2023.

2) What is the major growth driver of the Global IV and Oral Iron Drugs Market?

The major growth driver is the rising prevalence of iron deficiency anemia and chronic kidney disease.

3) Which is the largest region during the forecast period in the Global IV and Oral Iron Drugs Market?

North America is projected to remain the largest regional market through 2031.

4) Which segment accounted for the largest market share in the Global IV and Oral Iron Drugs Market?

The IV Iron Drugs segment held the largest market share in 2023.

5) Who are the key market players in the Global IV and Oral Iron Drugs Market?

Key players include Vifor Pharma, AMAG Pharmaceuticals, Sanofi, Pharmacosmos, and Shield Therapeutics.